The Indian government now requires a prescription for oral drug formulations containing more than 12% v/v ethyl alcohol in containers larger than 30 ml [1].
This regulatory shift aims to curb the unregulated sale and hoarding of medicinal products that contain high levels of alcohol. By tightening oversight, the Ministry of Health and Family Welfare seeks to prevent the misuse of these substances and improve overall public health safety [1], [3].
To implement these changes, the Centre amended the Drugs Rules, 1945 [2]. The amendment moves these specific high-alcohol formulations into Schedule H1 [2]. This classification ensures that the medications cannot be sold over the counter without a valid medical prescription from a licensed practitioner.
Under the new rules, pharmacies are required to maintain detailed sales records for these products [1]. This documentation is intended to create a transparent audit trail, making it more difficult for individuals or entities to stockpile high-alcohol medicines for non-medical purposes [3].
The announcement of the amendment occurred on July 10, 2026 [2]. The rules specifically target oral formulations where the alcohol content exceeds the 12% v/v threshold [1] and the volume of the container is greater than 30 ml [1]. Smaller containers or those with lower alcohol concentrations remain subject to previous regulations.
Officials said the move is a necessary step to strengthen the regulation of drug formulations [2]. By integrating these products into Schedule H1, the government aligns the sale of high-alcohol medicines with other restricted drugs that require strict professional supervision [2].
“The Indian government now requires a prescription for oral drug formulations containing more than 12% v/v ethyl alcohol”
This move represents a strategic effort by India to close regulatory loopholes that allowed high-alcohol medicines to be accessed without medical oversight. By utilizing Schedule H1, the government is treating these formulations similarly to potent narcotics or psychiatric drugs, shifting the burden of proof for necessity onto the patient, and the responsibility for compliance onto the pharmacist.
